Loading...

CytoTools

DB:T5O
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
T5O
DB
€21M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The last earnings update was 206 days ago. More info.


Add to Portfolio Compare Print
  • CytoTools has significant price volatility in the past 3 months.
T5O Share Price and Events
7 Day Returns
1.2%
DB:T5O
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
16%
DB:T5O
-10.2%
DE Biotechs
-6%
DE Market
T5O Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CytoTools (T5O) 1.2% 15% 47.7% 16% -23.3% -80.6%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • T5O outperformed the Biotechs industry which returned -10.2% over the past year.
  • T5O outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
T5O
Industry
5yr Volatility vs Market

T5O Value

 Is CytoTools undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of CytoTools to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for CytoTools.

DB:T5O Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:T5O
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30%) (13.43%))
1.391
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.391 * 5.96%)
8.52%

Discounted Cash Flow Calculation for DB:T5O using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for CytoTools is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:T5O DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.52%)
2019 -8.90 Analyst x1 -8.20
2020 -8.50 Analyst x1 -7.22
2021 -9.50 Analyst x1 -7.43
2022 5.30 Analyst x1 3.82
2023 21.90 Analyst x1 14.55
2024 36.30 Est @ 65.78% 22.23
2025 53.05 Est @ 46.11% 29.93
2026 70.20 Est @ 32.35% 36.50
2027 86.15 Est @ 22.71% 41.27
2028 99.90 Est @ 15.97% 44.11
Present value of next 10 years cash flows €169.56
DB:T5O DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €99.90 × (1 + 0.23%) ÷ (8.52% – 0.23%)
€1,207.64
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,207.64 ÷ (1 + 8.52%)10
€533.17
DB:T5O Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €169.56 + €533.17
€702.73
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €702.73 / 2.12
€331.44
DB:T5O Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:T5O represents 0.99797x of XTRA:T5O
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99797x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 331.44 x 0.99797
€330.77
Value per share (EUR) From above. €330.77
Current discount Discount to share price of €9.84
= -1 x (€9.84 - €330.77) / €330.77
97%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price CytoTools is available for.
Intrinsic value
>50%
Share price is €9.84 vs Future cash flow value of €330.77
Current Discount Checks
For CytoTools to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • CytoTools's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • CytoTools's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CytoTools's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CytoTools's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:T5O PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.50
XTRA:T5O Share Price ** XTRA (2019-04-18) in EUR €9.86
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CytoTools.

DB:T5O PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:T5O Share Price ÷ EPS (both in EUR)

= 9.86 ÷ -0.50

-19.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytoTools is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CytoTools is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CytoTools's expected growth come at a high price?
Raw Data
DB:T5O PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CytoTools, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CytoTools's assets?
Raw Data
DB:T5O PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €4.97
XTRA:T5O Share Price * XTRA (2019-04-18) in EUR €9.86
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:T5O PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:T5O Share Price ÷ Book Value per Share (both in EUR)

= 9.86 ÷ 4.97

1.98x

* Primary Listing of CytoTools.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytoTools is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CytoTools's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CytoTools has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

T5O Future Performance

 How is CytoTools expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
66.9%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is CytoTools expected to grow at an attractive rate?
  • Unable to compare CytoTools's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare CytoTools's earnings growth to the Germany market average as no estimate data is available.
  • CytoTools's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:T5O Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:T5O Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 66.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:T5O Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:T5O Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 100 23 1
2022-12-31 44 5 1
2021-12-31 11 -9 1
2020-12-31 5 -8 1
2019-12-31 1 -9 1
2018-12-31 0 -5 1
DB:T5O Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -1 -1
2018-03-31 0 -1 -1
2017-12-31 0 -1 -1
2017-09-30 0 -1 -1
2017-06-30 -1 -1
2017-03-31 -1 -1
2016-12-31 -1 -1
2016-09-30 -1 -1
2016-06-30 -1 -1
2016-03-31 -1 -1
2015-12-31 -1 -1
2015-09-30 0 -2 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if CytoTools is high growth as no earnings estimate data is available.
  • CytoTools's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:T5O Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from CytoTools Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T5O Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31
DB:T5O Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30
2018-03-31
2017-12-31 -0.50
2017-09-30 -0.50
2017-06-30
2017-03-31
2016-12-31 -0.49
2016-09-30 -0.54
2016-06-30
2016-03-31
2015-12-31 -0.66
2015-09-30 -0.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CytoTools will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CytoTools's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CytoTools has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

T5O Past Performance

  How has CytoTools performed over the past 5 years?

  • CytoTools's last earnings update was 206 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CytoTools's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CytoTools does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CytoTools's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CytoTools's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CytoTools's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CytoTools Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T5O Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.09 -1.15 0.31
2018-03-31 0.09 -1.11 0.32
2017-12-31 0.09 -1.07 0.33
2017-09-30 0.04 -1.06 0.33
2017-06-30 -1.06 0.34
2017-03-31 -1.02 0.33
2016-12-31 -0.98 0.32
2016-09-30 -1.09 0.36
2016-06-30 -1.20 0.40
2016-03-31 -1.25 0.42
2015-12-31 -1.30 0.44
2015-09-30 0.00 -1.34 0.38
2015-06-30 0.00 -1.37 0.32
2015-03-31 0.15 -1.20 0.32
2014-12-31 0.30 -1.04 0.32
2014-09-30 0.31 -0.91 0.40
2014-06-30 0.33 -0.79 0.48
2014-03-31 0.19 -0.96 0.51
2013-12-31 0.05 -1.14 0.54
2013-09-30 0.05 -1.03 0.47
2013-06-30 0.05 -0.92 0.41
2013-03-31 0.05 -0.79 0.36
2012-12-31 0.05 -0.66 0.31
2012-09-30 0.05 -0.71 0.30
2012-06-30 0.05 -0.77 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CytoTools has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CytoTools has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CytoTools improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CytoTools's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CytoTools has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

T5O Health

 How is CytoTools's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CytoTools's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CytoTools's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • CytoTools's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CytoTools's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CytoTools Company Filings, last reported 9 months ago.

DB:T5O Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 10.92 2.81 1.64
2018-03-31 10.92 2.81 1.64
2017-12-31 10.54 0.10 2.06
2017-09-30 10.54 0.10 2.06
2017-06-30 10.88 0.00 2.06
2017-03-31 10.88 0.00 2.06
2016-12-31 10.01 0.00 1.42
2016-09-30 10.01 0.00 1.42
2016-06-30 10.42 0.00 1.87
2016-03-31 10.42 0.00 1.87
2015-12-31 10.87 0.00 3.28
2015-09-30 10.87 0.00 3.28
2015-06-30 8.06 0.00 0.50
2015-03-31 8.06 0.00 0.50
2014-12-31 8.52 0.00 0.73
2014-09-30 8.52 0.00 0.73
2014-06-30 8.15 0.00 0.43
2014-03-31 8.15 0.00 0.43
2013-12-31 8.10 0.00 1.82
2013-09-30 8.10 0.00 1.82
2013-06-30 8.74 0.00 3.89
2013-03-31 8.74 0.00 3.89
2012-12-31 6.20 0.00 1.30
2012-09-30 6.20 0.00 1.30
2012-06-30 6.03 0.00 2.03
  • CytoTools's level of debt (25.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 25.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CytoTools has sufficient cash runway for 1.2 years based on current free cash flow.
  • CytoTools has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -26.6% each year.
X
Financial health checks
We assess CytoTools's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CytoTools has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

T5O Dividends

 What is CytoTools's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CytoTools dividends.
If you bought €2,000 of CytoTools shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CytoTools's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CytoTools's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:T5O Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:T5O Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CytoTools has not reported any payouts.
  • Unable to verify if CytoTools's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CytoTools's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CytoTools has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CytoTools's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CytoTools afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CytoTools has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

T5O Management

 What is the CEO of CytoTools's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark-André Freyberg
TENURE AS CEO 19.3 years
CEO Bio

Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer and Chairman of Management Board also served as its Managing Director. Dr. Freyberg served as the Head of Project, Cell Culture Technology at the Institute for Biochemistry at Darmstadt Technical University. In, 2000, he became a Co-Founder and Chief Executive Officer of CytoTools AG. There, he coordinated research activities and was responsible for the successful first round financing. Furthermore, support was obtained from BioChance, the largest German biotechnology funding program from the German Federal Ministry for Education and Research. Under Dr. Freyberg's leadership, the results of the basic research reached the stage of proof of conception in three animal models. Parallel to this, working was extended to the indications wound healing and dermatology. The medical successes led to the foundation of DermaTools Biotech GmbH in 2004 and TemplaTech GmbH in 2005 where he is also Chief Executive Officer. He has special responsibility for the fields of marketing of active substances and financing at CytoTools AG. After completing his diploma studies in biology, focusing on microbiology, in 1995 , Dr. Freyberg completed a doctorate in the fields of biochemistry and biotechnology at Darmstadt Technical University. Concomitantly with his dissertation, he additionally studied business science at the Hagen Distance Learning University.

CEO Compensation
  • Insufficient data for Mark-André to compare compensation growth.
  • Insufficient data for Mark-André to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Mark-André Freyberg

TITLE
Chairman of Management Board & CEO
TENURE
19.3 yrs

Peter Friedl

TITLE
Vice-Chairman of Management Board

Dirk Kaiser

TITLE
Co-Founder & Member of Management Board
Board of Directors

Manfred May

TITLE
Chairman of Supervisory Board

Herr Hoffmann

TITLE
Member of Supervisory Board

Rüdiger Weseloh

TITLE
Member of Supervisory Board

Jutta Schnirring-Mayer

TITLE
Member of Supervisory Board
TENURE
2.7 yrs

Heiner Hoppmann

TITLE
Member of Supervisory Board
AGE
60
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CytoTools's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CytoTools has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

T5O News

Simply Wall St News

T5O Company Info

Description

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.

Details
Name: CytoTools AG
T5O
Exchange: DB
Founded: 2000
€20,905,684
2,120,252
Website: http://cytotools.de
Address: CytoTools AG
Klappacher Strasse 126,
Darmstadt,
Hessen, 64285,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA T5O Bearer Shares XETRA Trading Platform DE EUR 13. Dec 2006
OTCPK CYTT.F Bearer Shares Pink Sheets LLC US USD 13. Dec 2006
DB T5O Bearer Shares Deutsche Boerse AG DE EUR 13. Dec 2006
Number of employees
Current staff
Staff numbers
0
CytoTools employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:08
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2018/09/28
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.